SUPPORTING INFECTIOUS DISEASE RESEARCH

Genomic DNA from Vaccinia Virus, Lister (Elstree)

Catalog No. NR-2635

For research use only. Not for use in humans.

Contributor:

ATCC[®]

Manufacturer:

BEI Resources

Product Description:

Genomic DNA was isolated from a preparation of cell lysate and supernatant from African green monkey cells (Vero; ATCC[®] CCL-81[™]) infected with vaccinia virus, Lister (Elstree). Vaccinia virus, Lister (Elstree) was originally isolated from the skin of a sheep. The Lister (Elstree) strain was widely used during the World Health Organization program on the eradication of smallpox.¹ The complete genomic sequence of vaccinia virus, Lister (Elstree) has been determined (GenBank: <u>AY678276</u>).²

NR-2635 has been qualified for PCR applications by amplification of an approximately 1100 base pair sequence. NR-2635 is <u>not</u> intended for use as a standard for quantitative PCR. Recommended dilutions for successful RT-PCR amplification are indicated on the Certificate of Analysis for each lot.

Material Provided:

Each vial contains a target amount of 1×10^8 copies of viral genomic DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) containing sodium azide. The actual number of copies per vial may vary from 10-fold lower to 10-fold higher. The number of copies per vial and the concentration are shown on the Certificate of Analysis. The viral genomic DNA is in a background of cellular nucleic acid and carrier RNA. The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-2635 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Genomic DNA from Vaccinia Virus, Lister (Elstree), NR-2635."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and

Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see <u>www.cdc.gov/biosafety/publications/bmbl5/index.htm</u>.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC[®] nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Ober, B. T., et al. "Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus Ankara." <u>J. Virol.</u> 76 (2002): 7713-7723. PubMed: 12097585.
- Morikawa, S., et al. "An Attenuated LC16m8 Smallpox Vaccine: Analysis of Full-Genome Sequence and Induction of Immune Protection." J. Virol. 79 (2005): 11873-11891. PubMed: 16140764.

ATCC[®] is a trademark of the American Type Culture Collection.



BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898